

## Meeting of the Board of Directors of CILEx Regulation Ltd on

Tuesday 15 April 2025

via Teams

Click here to join the meeting

Becky Mckune Email: <u>becky.mckune@cilexregulation.org.uk</u> John Barwick Chief Executive Officer

## AGENDA

09:30 – 10:00 Session 1 - Private Discussion							
10:00 Session 2 - Public Session							
ITEM No.	ITEM/ PAPER	ACTION	LEAD	TIME			
WELCOME & INTRODUCTIONS							
1.	Apologies			10.00am			
2.	Declarations of interest	N	Chair				
3.	Minutes of previous meetings and Action Log 03.01 Minutes – 11 February 2025 03.02 Action Log	A	Chair				
4.	Chair's update (oral report)	N	Chair				
5.	<ul> <li>Chief Executive's Report</li> <li>05.01 Corporate Plan Deliverables Progress Report</li> <li>05.02 Strategic Risk Register (SR1-4)</li> <li>05.03 Regulatory Performance Assessment 2023 Action Plan</li> <li>05.04 Regulatory Performance Assessment Report 2024</li> </ul>	D N	CEO				
6.	Risk Appetite Statement)	D	CEO				
Break 10.45 – 11.00							
7.	Director of Regulation's Report	N	DoR				
8.	Application and Assessor Fee Proposal	A	DoR				
9.	Director of Governance's Report	Ν	DoR				
10.	Annual Cycle of Business	N	All				



11.	AOB	D	All				
	Session 3 - Private Session						
12.	Financial Update NOT FOR PUBLICATION	D	CEO/FM				
	12.00 Finance Paper 12.01 Feb 2025 Management Accounts						

Key to Actions A = Approval;	Schedule of Future Meetings & Telecons				
D = Discussion; N = Noting	Date	Name of Board meeting	Timings		
Extract Governance Transparency Policy:	15/05/2025	CRL Board Strategy (Day 1)	12:00-18:00		
The Board may consider it justifiable for all	16/05/2025 17/06/2025	CRL Board Strategy (Day 2) Board Telecon	09:00-13:00 13:00-14:00		
or part of papers and minutes to be	15/07/2025	CRL Board	09:00-15:00		
excluded from publication on grounds that they:	17/09/2025	CRL Board	09:00-15:00		
a) are commercially sensitive;	06/11/2025	Board Telecon	13:00-14:00		
b) include legal or other professional	09/12/2025	CRL Board	09:00-15:00		
<ul> <li>advice on sensitive or confidential matters;</li> <li>c) involve matters concerning a named individual, an individual who can be identified or who has a reasonable expectation that the matter will remain confidential;</li> <li>d) contain personal data;</li> <li>e) include discussion of risk that might be exacerbated by publication;</li> <li>f) relate to emerging strategy or policy.</li> </ul>					